Crossmark

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program

Crossref DOI link: https://doi.org/10.1007/s13555-022-00853-4

Published Online: 2022-11-27

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gulliver, Wayne https://orcid.org/0000-0002-5990-232X
Gooderham, Melinda J. https://orcid.org/0000-0001-8926-0113
Zhu, Baojin https://orcid.org/0000-0003-4462-1856
Jossart, Christian https://orcid.org/0000-0002-5342-7409
Montmayeur, Sonia https://orcid.org/0000-0002-1986-3194
Burge, Russel https://orcid.org/0000-0001-7907-6400
Reed, Catherine https://orcid.org/0000-0002-4150-4569
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2022-11-27

Version of Record valid from 2022-11-27
More Information

Article History

Received: 27 August 2022

Accepted: 4 November 2022

First Online: 27 November 2022